ClinicalTrials.gg
Enrolling by invitationNCT07113743Updated Sep 8, 2026

Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease

A Phase 1/2 interventional study of Busulfan and Tocilizumab in Chronic Granulomatous Disease (CGD), sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Enrolling by invitation at 1 site in United States. Open to participants aged 3 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
3 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Granulomatous Disease, Chronic by National Institute of Allergy and Infectious Diseases (NIAID) — 7 open to participants now, 10 under way, none of them phase 3. Granulomatous Disease, Chronic · National Institute of Allergy and Infectious Diseases (NIAID).

Planned enrollment
12th of 24
10 · median 10
Started
2025
the only one that year
Phase 1/2
8 of 31
4 open now
Registered
31st of 31
by date

Among the 31 studies in Granulomatous Disease, Chronic by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 12th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2025, is one of 8 in phase 1/2, and was the 31st registered.

Granulomatous Disease, Chronic

79 studies on the registry are indexed under Granulomatous Disease, Chronic; 17 are open to participants now.

Browse Granulomatous Disease, Chronic studies →

Open to participants now

7 of the 31 studies in Granulomatous Disease, Chronic by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 12 Granulomatous Disease, Chronic studies recruiting now, 3 (25%) set no upper age limit and 9 (75%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 3 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Granulomatous Disease, Chronic by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

Background:

X-Linked Chronic Granulomatous Disease (X-CGD) is caused by a gene mutation that makes the immune system to not work properly. Researchers want to see if a lentiviral gene transfer treatment will have the ability to make the patient s immune system more normal, in particular reduce the risk of CGD related infections. The gene transfer takes a person s own stem cells, cultures them to put the normal gene in, then gives the cells back to the person.

Objective:

To test a gene transfer treatment for X-CGD.

Eligibility:

Participants aged 3-60 with X-CGD

Design:

Participants will be screened under protocol 05-I-0123. They will undergo:

Medical history

Physical exam

Heart tests

Imaging tests, as needed

Blood tests

Lung function tests, as needed

Dental and audiology exams, if needed

Quality of life questionnaire

Bone marrow aspiration. A needle will be inserted into the hip bone or breastbone to collect bone marrow.

Some screening tests will be repeated during the study.

Participants will have an apheresis procedure under protocol 94-I-0073. Stem cells will be collected.

Participants will get a series of drugs to prepare them for the gene transfer.

Participants will stay at the NIH Clinical Center for a little over a month. They will get a central line. It is a large intravenous (IV) catheter that is placed into a vein of the neck, chest, or arm. They will get chemotherapy and their corrected stem cells through their IV line.

Participants will have 12 follow-up outpatient visits in the 2 years after their gene transfer, as well as visits with their local doctor. Then they will enroll in another study for long-term follow-up visits that will last for 13 years.

Read the detailed description

Study Description:

This is a Phase I/II, non-Randomized, Single site study, open-label study of a single infusion of autologous CD34+ cells transduced ex vivo with pCCLChimGp91/VSVg lentiviral vector in 10 patients with X-Linked CGD.

Objectives:

Primary Objective:

To evaluate the safety, efficacy and stability by biochemical and functional reconstitution in progeny of engrafted cells at 12 months Secondary Objectives:

Endpoints:

  • Clinical efficacy and longitudinal evaluation of clinical effect in terms of augmented immunity against bacterial and fungal infection
  • Determine the number of days of antibiotic usage before compared to after gene therapy
  • Transduction efficiency of CD34+ hematopoietic cells from XCGD patients by ex vivo lentivirus-mediated gene transfer
  • Evaluation of engraftment kinetics and stability

Primary Endpoint:

  1. The primary safety objective of this procedure will be assessed by recording the incidence of adverse events.

    1. Record clinical adverse events and clinically significant laboratory abnormalities.
    2. Evaluate overall incidence of adverse events for the study as a whole.
    3. Monitor the incidence of serious adverse events.
  2. The primary efficacy objective of this study will be determined by measuring the percentage of subjects who have >= 10% oxidase positive granulocytes by dihydrorhodamine (DHR) flow cytometry at month 6 and 12 after transplant.

Secondary Endpoints:

  1. Assess immunological reconstitution:

    Restoration of neutrophil oxidase function (> 10%) as measured by DHR flow cytometry (clinical), and/or cytochrome C (O2 production, research), at 24 months. The % DHR + neutrophils will be measured at week 4, 5, 6, 7, 8, 10, 12 and month 6, 9, 12, 18 and 24.

  2. Assess hematopoietic stem cell (HSC) transduction and engraftment:

    1. Determine the percentage of transduced CD34+ hematopoietic cells infused.
    2. Measure the average vector copy number (VCN) in mature blood cells (at week 4, 6, 7, 8, 10, 12 and month 6, 9, 12, 18 and 24) by quantitative polymerase chain reaction (qPCR) or droplet digital polymerase chain reaction (ddPCR).
  3. Assess health by:

    1. The nutritional status (height, weight, serum albumin) at 24 months
    2. Growth and development of pediatric subjects at 24 months
    3. Frequency of severe infections or other health issues, including inflammatory complications (requiring intravenous [IV] antibiotics and/or hospitalization for treatment)
    4. Measurement of inflammatory markers at 1, 2, 3, 6, 9, 12, 18, and 24 months, compared to baseline
    5. Colitis assessment based on CDAI (Crohn s Disease Activity Index) and fecal calprotectin at 6, 12, and 24 months, compared to baseline
    6. Quality of Life (QOL) questionnaire (baseline, 6, 12 and 24 months)

Exploratory Endpoints:

  1. Evaluation of the human microbiome during XCGD gene therapy
  2. Evaluation of inflammatory cytokines and antibody development to Gp91, etc
03

Conditions studied

  • Chronic Granulomatous Disease (CGD)

Keywords

  • Gene Therapy
  • UCLA
  • CGD
04

Who can participate

Ages eligible
3 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

-Must have confirmed molecular diagnosis of X-linked CGD confirmed by deoxyribonucleic acid (DNA) sequencing and supported by laboratory evidence for absent or reduction >90% of the biochemical activity of the NADPH-oxidase.

  • At least 1 prior ongoing or severe infection and/or inflammatory complications requiring hospitalization despite conventional therapy.
  • No 10/10 HLA-matched donor available after initial search of National Marrow Donor Program (NMDP) registries within the last year.
  • Must weigh at least 15 kg.
  • Male or female, and must be at least 3 years of age but no older than 60.
  • Parent/guardian must be willing to sign and date form for child and where appropriate, child may sign assent.
  • Stated willingness to comply with all study procedures and availability for the duration of the study.
  • Ability to take oral medication and be willing to adhere to the prophylactic regimen.
  • Apheresis of patients for the hematopoietic stem cells collected as a part of this protocol will be performed according to the Standard of Care apheresis practices established in the NIH CC Department of Transfusion Medicine or at their local facility. If performed at

their local institution, the patient will have consented onto the gene therapy study prior to collection; however, products collected prior to the study for other protocols may be used as part of the backup. Patients who are apheresed at the NIH may be apheresed on

another protocol.

-For apheresis, pediatric patients:

  • Must weigh at least 15 kg body weight;
  • Preserved renal function (creatinine \<=2.5 mg/dL; \<=3+ proteinuria); preserved hepatic function ( \<=2.0 mg/dl);

    -Must be negative for co-infection with (HIV) or virus (HBsAg positive) or virus (HCV ribonucleic acid (RNA) positive), adenovirus, parvovirus B 19 or toxoplasmosis or mycobacterial infection (prior or current).

    -For females of , must agree to use of 2 highly effective throughout study participation and for at least 3 months after the study.

    • For females:
  • Condoms, male or female, with or without a spermicide;
  • Diaphragm or cervical cap with spermicide;
  • Intrauterine device;
  • Contraceptive pills or patch, Norplant, Depo-Provera, or other FDA- approved contraceptive method;

    • For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.
    • Agreement to adhere to Lifestyle Considerations throughout study duration.
    • Ability of subject (Patient/Legal Guardian) to understand and the willingness to sign a written informed consent document.
    • For the Natural History Protocol (05-I-0213): All patients must be willing to allow storage of blood samples for future studies.
    • Must provide a durable power of attorney (DPA) for health care decisions to an appropriate adult relative or guardian in accordance to NIH-200 "NIH Advance Directive for Health Care and Medical Research Participation."

Exclusion criteria

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

-Patient/Parent/Guardian unable or unwilling to comply with the protocol requirements.

  • for leukapheresis (anemia \<8 g/dl, cardiovascular instability, severe coagulopathy).
  • Patients who are unable to lie prone during the bone marrow harvesting procedure (in the case of bone marrow harvest, contraindication to general anesthesia).
  • Have a 10/10 HLA identical (A,B,C,DR,DQ) family or unrelated adult donor unless there is deemed to be an unacceptable risk associated with an allogeneic procedure.
  • Tested positive (definitive) for the presence of multiple types (2 or more) of anti- antibodies.
  • Altered organ function as outlined below observed within 8 weeks of entering this trial.

    1. Hematologic

    i. Anemia (hemoglobin \< 8 g/dl).

ii. Neutropenia (absolute granulocyte count \<1,000/mm3 ).

iii. Thrombocytopenia (platelet count \< 150,000/mm3).

iv. (PT) INR or Partial thromboplastin time (PTT) > 2 X the (ULN) (patients with a correctable deficiency controlled on medication will not be excluded).

v. Cytogenetic abnormalities known to be associated with hematopoietic defect on peripheral blood or bone marrow.

b. Infectious

i. Evidence of infection with -1 and -2, , , adenovirus, parvovirus B 19 or toxoplasmosis within 8 weeks prior to mobilization/apheresis or bone marrow harvest. Cytomegalovirus (CMV) infection is allowable as long as the infection is under control.

ii. History of infection with mycobacteria or Bacille Calmette-Guerin (BCG) vaccination.

c. Pulmonary

i. Resting O2 saturation by pulse oximetry \< 90% on room air.

d. Cardiac

i. Abnormal (ECG) indicating cardiac pathology.

ii. Uncorrected congenital cardiac malformation with clinical symptomatology.

iii. Active cardiac disease, including clinical evidence of congestive heart failure, cyanosis, hypotension.

iv. Poor cardiac function as evidenced by LV \<40% on echocardiogram.

e. Neurological

i. Significant neurologic abnormality by examination.

ii. Uncontrolled seizure disorder.

f. Renal

i. Renal insufficiency: serum creatinine >=2.5 mg/dl, or >=3+ proteinuria.

  • Chemistry Lab abnormalities: Serum sodium >= 156 mmol/L or \<= 129 mmol/L, potassium >= 6.1 mmol/L or \<= 2.9 mmol/L, calcium >= 3.2 mmol/L or \< 1.74 mmol/L , magnesium >= 1.24 mmol/L or \< 0.39 mmol/L, phosphate >= 5.1 mmol/L or \< 1.9 mmol/L.
  • Serum transaminases > 5X the upper limit of normal (ULN).

Serum > 2X the upper limit of normal (ULN).

Serum glucose > 1.5X the upper limit of normal (ULN).

  • General

    • Expected survival \< 6 months.
    • Major congenital anomaly.
    • Known allergic reactions to components of busulfan or dimethyl sulfoxide (DMSO) or contraindication for administration of conditioning medication.
    • Evidence of active malignant disease.
  • Treatment with another drug or other intervention within 6 months.
  • Unable to undergo apheresis as per the NIH CC Department of Transfusion Medicine Standard of Care apheresis procedures.

    1. Patients who are hemodynamically unstable (systolic or diastolic blood pressure fall of 20 mm Hg from the stable patient's baseline measurement) or requiring mechanical respiratory assistance are excluded.

History of vasculitis.

  • Administration of gamma-interferon within 21 days before the infusion of transduced, autologous CD34+ cells.
  • Any other condition that, in the opinion of the Investigator, may compromise the safety or compliance of the patient or would preclude the patient from successful study completion.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    X-linked CGD

    Non-randomized single arm

    Drug: Busulfan · Drug: Tocilizumab · Drug: Eltrombopag · Drug: Sirolimus · Other: pCCLChimGp91lentiviral vector containing the human gp91 phox (CYBB) gene

Interventions

  • Conditioning drug

  • Monoclonal Antibody

  • Thrombopoietin Receptor Agonist

  • Post transplant immunosuppressant drug

  • OtherpCCLChimGp91lentiviral vector containing the human gp91 phox (CYBB) gene

    Intervention Infusion on Day 0

06

What researchers measure

Primary outcomes

  1. Safety

    1\) The primary safety objective of this procedure will be assessed by recording the incidence of adverse events. a) Record clinical adverse events and clinically significant laboratory abnormalities. b) Evaluate overall incidence of adverse events for the study as a whole. c) Monitor the incidence of serious adverse events.

    Time frame: Throughout the study

  2. Efficacy

    The primary efficacy objective of this study will be determined by measuring the percentage of subjects who have \>= 10% oxidase positive granulocytes by DHR flow cytometry at month 6 and 12 after transplant.

    Time frame: 6 months and 1 year

Secondary outcomes

  1. Assess immunological reconstitution

    Restoration of neutrophil oxidase function (\> 10%) as measured by DHR flow cytometry (clinical), and/or cytochrome C (O2 production, research), at 24 months. The % DHR + neutrophils will be measured at week 4, 5, 6, 7, 8, 10, 12 and months 6, 9, 12, 18 and 24 months.

    Time frame: Week 4, 5, 6, 7, 8, 10, 12 and months 6, 9, 12, 18 and 24 months.

  2. Assess HSC transduction and engraftment

    a) Determine the percentage of transduced CD34+ hematopoietic cells infused. b) Measure the average vector copy number (VCN) in mature blood cells (at week 4, 6, 7, 8, 10, 12 and month 6, 9, 12, 18 and 24) by qPCR or ddPCR.

    Time frame: Week 4, 6, 7, 8, 10, 12 and month 6, 9, 12, 18 and 24)

  3. Assess health by

    a) The nutritional status (height, weight, serum albumin) at 24 months b) Growth and development of pediatric subjects at 24 months c) Frequency of severe infections or other health issues, including inflammatory complications (requiring IV antibiotics and/or hospitalization for treatment) d) Measurement of inflammatory markers at 1, 2, 3, 6, 9, 12, 18, and 24 months, compared to baseline e) Colitis assessment based on CDAI (Crohn s Disease Activity Index) and fecal calprotectin at 6, 12, and 24 months, compared to baseline f) Quality of life questionnaire (baseline, 6, 12 and 24 months).

    Time frame: 1, 2, 3, 6, 9, 12, 18, and 24 months, compared to baseline

07

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Sep 2028, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Aug 11, 2025
StartActual
Sep 10, 2025
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2029
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07113743
Responsible party
Sponsor
First posted
Aug 11, 2025
Start date
Sep 10, 2025
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Sep 8, 2026

Study contacts

Elizabeth M Kang, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Busulfan · Tocilizumab · Eltrombopag · Sirolimus

Start the discussion